BioMarin Pharmaceutical Inc.
766 articles with BioMarin Pharmaceutical Inc.
-
The 12 Top Biotech Companies Hiring Now
5/10/2022
According to recent BioSpace research, job seekers are on the prowl for roles that are interesting and pay well with good benefits at reputable companies. -
BioMarin to Present Findings from Ongoing Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the World Federation of Hemophilia 2022 World Congress, May 8-11, 2022, Including Five Platform Presentations
5/5/2022
BioMarin Pharmaceutical Inc. today announced five platform presentations and one poster presentation on valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, at the World Federation of Hemophilia (WFH) 2022 World Congress from May 8-11 in Montreal, Canada.
-
BioMarin Hires Pharmaceutical Industry Leaders in Marketing and Accounting to Fill Strategic Roles Supporting Company's Growth Plans
5/5/2022
BioMarin Pharmaceutical Inc. announced that the Company hired two pharmaceutical industry leaders in their respective areas of expertise.
-
BioMarin to Participate in the BofA Securities 2022 Healthcare Conference, Thursday, May 12 at 8:40amPT/11:40amET
5/4/2022
BioMarin Pharmaceutical Inc., announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will present at the BofA Securities Healthcare Conference on May 12 at 8:40am PT/11:40am ET in Las Vegas.
-
The Q1 results for Voxzogo gave BioMarin the confidence to raise its 2022 full-year guidance to between $100 million to $125 million (net product revenue) for the drug.
-
BioMarin Announces Record Revenues in First Quarter 2022
4/27/2022
BioMarin Pharmaceutical Inc. announced financial results for the first quarter ended March 31, 2022.
-
In honor of World Hemophilia Day, BioSpace takes a look at some of the facts relating to the disease, and some of the highlights in recent hemophilia research and development.
-
BioMarin to Host First Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, April 27, at 4:30pm ET
4/13/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, April 27th, at 4:30 p.m. ET to discuss first quarter 2022 financial results and provide a general business update.
-
It was a busy week for clinical trial announcements. Here's a look.
-
BioMarin Pharmaceuticals Hemophilia A Data Indicate Potential for "Sustained Bleed Control"
3/18/2022
BioMarin Pharmaceuticals has published positive results in the New England Journal of Medicine from its Phase III clinical trial of valoctocogene roxaparvovec. -
BioMarin Announces Publication in New England Journal of Medicine of One-Year Results from Phase 3 Pivotal Trial with Valoctocogene Roxaparvovec Gene Therapy in Adults with Severe Hemophilia A
3/17/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced publication of results from the Phase 3 GENEr8-1 study of valoctocogene roxaparvovec, an investigational gene therapy for the treatment of adults with severe hemophilia A, in the New England Journal of Medicine (NEJM).
-
BioMarin Announces Fourth Quarter and Full Year 2021 Financial Results and Corporate Updates
2/23/2022
BioMarin Pharmaceutical Inc. announced financial results for the fourth quarter and full-year ended December 31, 2021.
-
Silence Therapeutics, Totus Medicines and Poseida Therapeutics all adjust as they welcome new members to their leadership teams.
-
Biomarin indicated that the FDA had requested more data from non-clinical studies to evaluate the theoretical cancer risk to human trial participants. This is likely to take several quarters.
-
BioMarin Provides Updates on Progress in Gene Therapy Programs
2/17/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced updates on its investigational gene therapy programs in clinical development.
-
BioMarin to Participate in Two Upcoming Virtual Investor Conferences - Feb 16, 2022
2/16/2022
BioMarin Pharmaceutical Inc. announced that management will participate in two upcoming virtual conferences.
-
BioMarin to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on Wednesday, February 23 at 4:30pm ET
2/10/2022
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, February 23rd, at 4:30 p.m. ET to discuss fourth quarter and full year 2021 financial results and provide a general business update.
-
BioMarin Sells Priority Review Voucher for $110 Million
2/9/2022
BioMarin Pharmaceutical Inc. announced that it has entered into a definitive agreement with an undisclosed purchaser to sell the Rare Pediatric Disease Priority Review Voucher it obtained in November 2021 for a lump sum payment of $110,000,000.
-
Novartis CEO Vas Narasimhan and Roche CEO Severin Schwan saw revenue growth for the past year, and each took home more than $12 million in total compensation for 2021.
-
BioMarin Announces Oral Presentation of 2-Year Analysis of Largest Phase 3 Gene Therapy Study in Adults with Severe Hemophilia A at 15th Annual Congress of European Association for Haemophilia and Allied Disorders (EAHAD) 2-4 February
2/4/2022
BioMarin Pharmaceutical Inc. today announced that the Company presented positive results from a two-year analysis of the Phase 3 GENEr8-1 study.